Eterna Therapeutics
ERNA
8 hedge funds and large institutions have $4.79M invested in Eterna Therapeutics in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 1 reducing their positions, and 1 closing their positions.
0.33% less ownership
Funds ownership: 31.41% → 31.07% (-0.33%)
11% less funds holding
Funds holding: 9 → 8 (-1)
100% less capital inflows, than outflows
Capital inflows: $0 | Capital outflows: $208K
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AIC
AWM Investment Company
New York
|
-$104K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$104K |
| 3 |
Manulife (Manufacturers Life Insurance)
Canada,
Ontario, Canada
|
-$1K |
ERNA Hedge Fund Activity: Q3 2017 in Review
8 of the 4,023 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q3 2017, worth a combined $4.79M — down 11% from $5.36M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of ERNA and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest seller was AWM Investment Company, cutting an estimated $104K.
- 8 institutional investors held Eterna Therapeutics (ERNA) as of Q3 2017, down from 9 in Q2 2017.
- Funds reported $4.79M of Eterna Therapeutics stock for Q3 2017, down 11% quarter-over-quarter.
- 0 funds opened new Eterna Therapeutics positions in Q3 2017 and 1 closed out, a net change of -1 holder.
- The largest Eterna Therapeutics seller in Q3 2017 was AWM Investment Company, an estimated $104K sold.
Based on aggregated 13F filings for Q3 2017.